The Latest Breaking News from CRDF

Worries about sky-high inflation, the Federal Reserve’s hawkish stance, and recession prospects have spurred market sell-off lately. Moreover, investors expect increased market volatility as analysts cut down their earnings estimates. Given the uncertain market conditions, fundamentally weak and losing stocks Snap (SNAP), Allegiant Travel (ALGT), and Cardiff Oncology (CRDF) could…

The oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of quality oncology…

  Cardiff Oncology (NASDAQ:CRDF) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:10 PM. Here's what investors need to know about the announcement.

Cardiff Oncology Inc (NASDAQ: CRDF) posted